Publications
NET RETREAT the CCTG NE1 trial has recently opened in North America looking to compare retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment in patients with metastatic midgut neuroendocrine tumours.
Neoadjuvant Chemotherapy, Excision And Observation Vs Chemoradiotherapy For Early Rectal Cancer. The NEO-RT Trial
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma
OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults with Newly Diagnosed Multiple Myeloma
A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MYELOMATCH Clinical Trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
The CCTG SRC.6 (COG ARST1321) study is now closed to accrual.
Thanks to the hard work of many across the CCTG group and collaborative working processes with our pediatric colleagues the SRC.6 trial met its primary endpoint early. Addition of pazopanib to preoperative chemoradiation increased rates of complete pathological response for individuals with sarcoma. Additional follow up is planned to determine if this translates into improved event free and overall survival. A huge thank you to everybody who contributed to this success.
MA.39 - Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
The randomization of the first MA.39 patient has been completed by the Juravinski Cancer Centre at Hamilton Health Sciences on October 16, 2018 - Congratulations! This site is lead by the Study Chair Tim Whelan and has four additional patients registered.
The CCTG CEC.5 trial: A Phase II Study of Corticosteroid + Bevacizumab vs Corticosteroid + Placebo (BeST) for Radionecrosis after Radiosurgery for Brain Metastases has officially closed to accrual as of October 12, 2018.
Primary Objective: To investigate whether the addition of bevacizumab to standard corticosteroid therapy results in greater improvement in symptoms (clinical and patient-reported symptom improvement associated with radionecrosis and less radionecrosis treatment-induced symptoms) compared with standard corticosteroid therapy.
A new trial, Nivolumab, Ipilimumab in Patients With Hyper Mutated Cancers Detected in Blood (NIMBLe) will soon open at centers in the US and Canada. Trial researchers will initially explore the use of non-invasive approaches to confirm POLE and POLD1 mutations in solid tumors and to investigate whether those tumors are responsive to immunotherapy.
Why are cancer clinical trials important? Find out in this video interview with Dr. Rebecca Auer.
Canadian Cancer Trials group is providing an update about the previously planned BI.3 trial "A Phase II/III Trial Comparing Cisplatin Plus Acelarin to Cisplatin Plus Gemcitabine in First-Line Treatment of Locally Advanced or Metastatic Biliary Tract Cancer". The BI.3 trial will not be proceeding to move forward through the planned academic consortium as lead by CCTG, the partnering company has made a strategic decision to undertake the study as an industry-sponsored trial.
It is anticipated that RIPPLE (Roster Interface Program and Participants List Environment) version 3.0 will be rolled out on October 19, 2018.